Next Article in Journal
Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach
Next Article in Special Issue
The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape
Previous Article in Journal
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3
Previous Article in Special Issue
A Matched-Pair Analysis after Robotic and Retropubic Radical Prostatectomy: A New Definition of Continence and the Impact of Different Surgical Techniques
 
 
Article
Peer-Review Record

Identification and Validation of a Novel Ferroptotic Prognostic Genes-Based Signature of Clear Cell Renal Cell Carcinoma

Cancers 2022, 14(19), 4690; https://doi.org/10.3390/cancers14194690
by Zhiyuan Shi 1,†, Jianzhong Zheng 1,†, Qing Liang 2,3, Yankuo Liu 1, Yi Yang 1, Rui Wang 2,3, Mingshan Wang 1, Qian Zhang 2,3, Zuodong Xuan 1, Huimin Sun 4, Kejia Wang 2,3,* and Chen Shao 1,*
Reviewer 1:
Reviewer 2: Anonymous
Cancers 2022, 14(19), 4690; https://doi.org/10.3390/cancers14194690
Submission received: 8 September 2022 / Revised: 22 September 2022 / Accepted: 23 September 2022 / Published: 27 September 2022
(This article belongs to the Special Issue Urological Cancer 2022)

Round 1

Reviewer 1 Report

Please check the attached PDF file

Comments for author File: Comments.pdf

Author Response

Dear reviewer,

Thanks for your suggestions. Here are our revision of manuscript.

Author Response File: Author Response.docx

Reviewer 2 Report

In this research, the author proposed a ferroptotic prognostic genes-based signature of clear cell renal cell carcinoma (ccRCC). Nine genes were individualized and used in this prognostic model. The crucial gene appeared to be glutaminase 2 (GLS2) which was up-regulated during ferroptosis in ccRCC cells. Cells with GLS2 shRNA displayed lower survival, lower glutathione level, and high lipid peroxide level, which illustrated that GLS2 might be a ferroptotic suppressor in ccRCC.

The paper is well written and a deep analysis has been performed.

I would like to suggest only some revisions:

- In the introduction section please report incidence and mortality only as numbers

- Prognostic models are fundamental to developing a personalized therapy, moreover, an early diagnosis is of paramount importance in these cases (doi: 10.3390/cancers14051112)

Author Response

Dear reviewer,

Thanks for your suggestions. Here are our revision of manuscript.

Author Response File: Author Response.docx

Back to TopTop